非转移去势抵抗性前列腺癌治疗新药——apalutamide

New drug for nonmetastatic castration-resistant prostate cancer——apalutamide

Apalutamide是一种口服的雄激素受体抑制剂,美国食品药品监督管理局批准其用于治疗非转移去势抵抗性前列腺癌患者。Apalutamide常见的不良反应包括皮疹、腹泻、疲劳、恶心、呕吐、高血压、血尿和骨折等。本文对apalutamide的药理作用、药物代谢动力学、临床评价、安全性、用法用量及药物相互作用等进行综述,旨在为临床用药提供参考。

Apalutamide is an androgen receptor inhibitor,which has been approved by Food and Drug Administration for the treatment of patients with nonmetastatic castration-resistant prostate cancer.The most common adverse events were rash,diarrhea,fatigue,nausea,vomiting,hypertension,hematuria and fracture.The pharmacology,pharmacokinetics,clinical research,safety,recommended dosage,and drug interactions of apalutamide wcre reviewed in this article.